nadofaragene firadenovec

Introduction

No yet FDA-approved.

Indications

• intravesicular treatmentof bladder cancer resistant to BCG

Dosage

• intravesicular administration every 3 months

Mechanism of action

• adenovirus vector-based gene therapy containing the interferon alfa-2b gene
• adenovirus enters cells of the bladder wall, the gene is transcribed, & the cells then secrete interferon alfa-2b protein
• response maintained at 12 months in 45% of patients

More general terms

• antineoplastic agent (chemotherapeutic agent)